
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
Nektar Therapeutics’ investigational T cell stimulator rezpegaldesleukin eases symptom burden in patients with atopic dermatitis, according to a Tuesday readout from the Phase IIb REZOLVE-AD trial. The company’s stock surged as much as 175% on that …